Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ESH AL 2018 | Exciting immunotherapy clinical trials for the management of AML

Marion Subklewe • 4 May 2018

ESH AL 2018

Acute Myeloid Leukemia Leukemia AMG 330 Antibodies Blinatumomab

Marion Subklewe, MD, from LMU Hospital Munich, Munich, Germany, discusses several clinical trials in acute myeloid leukemia (AML) that are currently underway, including a Phase I trial investigating MGD006 (NCT02152956), and a trial investigating the use of the anti-CD33/CD3 BiTE antibody, known as AMG 330, for the management of relapsed/refractory AML (NCT02520427). Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Dr Subklewe also discusses an upcoming trial that is in development to investigate the effects of a follow-up molecule of AMG 330.

CD33-TIM3 dual CAR T-cells enhance specificity of AML treatment

Marion Subklewe • 9 Dec 2023

MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial

Marion Subklewe • 9 Dec 2023

Dose escalation of RO7283420, a HLA-A2-WT1 CD3 T-cell bispecific antibody, in R/R AML

Marion Subklewe • 9 Dec 2023

Novel immunotherapies in AML and insights into the future of the treatment landscape

Marion Subklewe • 9 Dec 2023

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024